Perniola-Krajewska-Carnevale Syndrome

Perniola-Krajewska-Carnevale syndrome is a very rare genetic condition. Children are usually born healthy in terms of vital signs, but they show two main features: little or no hair (alopecia) and intellectual disability that can be mild to severe. Some children also have seizures, hearing loss, developmental delay, and changes in muscle tone. Doctors first described families with this pattern in medical journals, and later databases grouped them under the name “alopecia-intellectual disability (APMR) syndrome.” The condition is autosomal recessive, which means a child is affected when they inherit one non-working copy of a gene from each parent. It is extremely rare—reported in fewer than 20 families worldwide—and usually begins from newborn life. Orpha+2Rare Diseases Information Center+2

Alopecia–Intellectual Disability (APMR) syndrome—also called Perniola-Krajewska-Carnevale syndrome—is an extremely rare, inherited condition seen in fewer than a few dozen families worldwide. Children are born with complete or nearly complete hair loss (on the scalp and often eyebrows and eyelashes) and have mild to severe learning and developmental difficulties. Some children can also have seizures, sensorineural hearing loss (inner-ear hearing loss), delayed motor milestones, and muscle stiffness or increased tone. Doctors recognize at least four genetic subtypes (APMR1–APMR4). APMR1 is linked to variants in the AHSG gene; APMR4 is linked to variants in LSS (lanosterol synthase). The condition is usually autosomal recessive, which means a child is affected when both parents silently carry one altered gene copy. Wiley Online Library+4Rare Diseases Information Center+4NCBI+4

Why it happens

Hair growth and brain development both rely on tightly controlled cell signaling and lipid/sterol pathways. In APMR1, changes in AHSG (fetuin-A) are implicated; in APMR4, changes in LSS disrupt cholesterol/lanosterol synthesis steps that are important for hair follicles and for brain development. These gene problems do not usually make children sick in other organs, but they can disturb hair formation and neurodevelopment, leading to the main signs seen in this syndrome. NCBI+1

Scientists have learned that the syndrome is actually genetically diverse. In some families, disease-causing changes were found in a gene called LSS (lanosterol synthase), an enzyme that helps the body make cholesterol; in others, a change was reported in AHSG (fetuin-A). For still other families, the precise gene is not known yet, but the location on the chromosomes has been mapped. This explains why children can share the same “look” (hair loss + learning difficulties) but have small differences in other features. NCBI+2MalaCards+2

---

Other names

Doctors and reference centers use several names for the same condition. You may see:

• Alopecia-intellectual disability syndrome (APMR)

• Alopecia-mental retardation syndrome (older wording you’ll still see in older articles/databases)

• Perniola-Krajewska-Carnevale syndrome (eponym used in rare-disease listings)

• APMR1 / APMR2 / APMR3 / APMR4 (subtypes reflecting different genetic findings or mapped regions)

All of these describe the same core picture of near-total hair loss with cognitive disability. Orpha+2National Organization for Rare Disorders+2

---

Types

Clinicians often group this syndrome by the underlying gene or chromosome region. Think of them as “types” of the same clinical syndrome.

1. APMR1 – cases linked to the AHSG gene (fetuin-A). Only a small number of families have been reported; inheritance is autosomal recessive. MalaCards+1

2. APMR2 – families mapped to a region on chromosome 3q26.2-q26.31, gene not yet clearly identified. NCBI

3. APMR3 – families mapped to chromosome 18q11.2-q12.2, gene not yet clearly identified. NCBI

4. APMR4 – caused by changes in LSS (lanosterol synthase) on chromosome 21q22; this affects the cholesterol biosynthesis pathway, which is important for the developing brain and hair follicles. NCBI+1

Across these types, the shared signs are alopecia and intellectual disability. Other features can vary from family to family. Rare Diseases Information Center

---

Causes

In everyday language, “cause” here means what can lead to the syndrome or how a particular genetic change produces the features we see. Because this is a genetic disorder, the causes below are genetic mechanisms or well-documented risk patterns rather than environmental triggers.

1. Biallelic LSS variants (APMR4) – both copies of the LSS gene carry a change that reduces lanosterol synthase activity and disturbs cholesterol synthesis, which developing brain and hair follicles need. MalaCards

2. Biallelic AHSG variants (APMR1) – both copies of the AHSG gene carry a change; fetuin-A has roles in mineral handling and cellular signaling, and rare families with these variants show the APMR picture. MalaCards

3. APMR2 locus (3q26.2-q26.31) – a still-unknown gene in this mapped region; linkage studies connect families to this location. NCBI

4. APMR3 locus (18q11.2-q12.2) – another mapped region in which the causal gene remains to be discovered. NCBI

5. Autosomal-recessive inheritance – the fundamental pattern: a child inherits one silent copy from each carrier parent. Orpha

6. Missense mutations – single “letter” changes that swap one amino acid for another and reduce gene/protein function (reported for LSS and AHSG). MalaCards+1

7. Loss-of-function mutations – nonsense/frameshift changes that truncate a protein so it cannot work normally. (General genetic mechanism relevant to APMR genes.) NCBI

8. Splice-site mutations – changes at intron–exon boundaries that mis-assemble the RNA, producing a faulty protein. (Mechanism reported across many rare recessive disorders; applicable here.) NCBI

9. Regulatory/promoter variants – changes that lower gene expression enough to cause disease when both copies are affected. (A plausible mechanism in recessive conditions and mapped loci.) NCBI

10. Compound heterozygosity – two different damaging variants in the same gene, one from each parent, together causing disease (seen in LSS-related APMR4). MalaCards

11. Homozygosity from consanguinity – parents who are related are more likely to carry the same rare variant; many reported families are consanguineous. PMC

12. Pathway disruption in cholesterol biosynthesis – LSS sits in a key step; disturbed sterol composition harms neuronal development and hair shaft formation. MalaCards

13. Disruption of skin/hair follicle development programs – final common pathway linking these genes/loci to alopecia. (Synthesis from APMR literature.) PubMed

14. Abnormal neuronal development and synaptic function – a shared downstream effect explaining intellectual disability. (Synthesis based on APMR reviews.) PubMed

15. Founder effects – in small populations, a single ancestral variant can spread and appear in multiple affected families. (Often observed in ultra-rare recessive syndromes.) PubMed

16. Copy-number changes in or near an APMR gene – rare deletions/duplications could remove key exons or alter gene dosage. (Plausible genetic mechanism in mapped loci.) NCBI

17. Uniparental isodisomy (rare) – a child inherits two copies of the same parental chromosome segment carrying a recessive mutation. (General mechanism occasionally unmasking recessive disease.) NCBI

18. Pathogenic variants affecting protein stability – changes that make a protein degrade too quickly to do its job. (Mechanistic explanation consistent with missense effects.) MalaCards

19. Pathogenic variants affecting enzyme active sites – for LSS, changes can directly reduce catalytic activity. MalaCards

20. As-yet-undiscovered genes in the APMR “network” – reviews note that known genes do not explain all families, so additional genes are expected. PubMed

(Notes: Items 1–4 are specific, evidence-based genetic causes/loci. Items 5–20 explain the inheritance model and the realistic mutation/pathway mechanisms known or strongly expected for this recessive syndrome family.)

---

Symptoms and signs

1. Alopecia universalis or near-total scalp hair loss. The hallmark feature; eyebrows and eyelashes may also be absent. Rare Diseases Information Center

2. Sparse or thin body hair. Axillary and pubic hair can be reduced or absent. MalaCards

3. Mild to severe intellectual disability. Learning and problem-solving are below age expectations and need support. Rare Diseases Information Center

4. Global developmental delay. Slower progress in speech, motor skills, and daily activities. Rare Diseases Information Center

5. Seizures (in some children). Doctors may see convulsions or abnormal EEG. PubMed

6. Sensorineural hearing loss (reported). Some children need hearing aids or cochlear support. Rare Diseases Information Center

7. Abnormal muscle tone. Hypertonia (stiffness) is noted in some reports; others may have hypotonia in infancy. Rare Diseases Information Center+1

8. Microcephaly (small head) in some cases. A feature reported in the APMR spectrum. checkorphan.org

9. Short stature in some reports. Growth can be below average. checkorphan.org

10. Facial differences can be subtle or absent. Unlike 3MC syndrome, APMR usually lacks a consistent facial pattern; the core is hair + cognition. (Synthesis from summaries.) Rare Diseases Information Center

11. Speech delay. First words and phrase speech arrive late. MalaCards

12. Motor delay (sitting, walking). Physical milestones may come later and benefit from physiotherapy. MalaCards

13. Behavioral and learning challenges. Extra educational and behavioral supports are often needed. Rare Diseases Information Center

14. EEG abnormalities in seizure-prone children. Helps confirm and guide seizure care. PubMed

15. Normal internal organs in many cases. Aside from the brain/skin findings, many children have no major structural organ defects—another reason a focused genetic work-up is important. (Synthesis from case series.) PubMed

---

Diagnostic tests

A) Physical examination (bedside assessments)

1. Full hair and scalp exam. The doctor documents how much scalp hair is present and whether eyebrows/eyelashes are missing; in APMR, loss is usually extensive and lifelong. Rare Diseases Information Center

2. Skin and body-hair check. Looks for reduced axillary/pubic hair and any scaling or dryness that might suggest another hair disorder. MalaCards

3. Growth measurements. Height, weight, and head circumference are plotted to detect short stature or microcephaly, sometimes present in the APMR spectrum. checkorphan.org

4. Developmental assessment. Simple, structured questions and observations to screen for delays in speech, fine motor, gross motor, and daily living skills. Rare Diseases Information Center

5. Neurologic exam. Checks tone (hypertonia or hypotonia), reflexes, coordination, and signs that would prompt EEG or brain imaging. Rare Diseases Information Center

6. Hearing screen at the bedside. Age-appropriate screening (e.g., otoacoustic emissions in infants) to pick up possible sensorineural loss. Rare Diseases Information Center

B) “Manual” clinical tests (simple office-based procedures)

7. Hair pull test. The clinician gently pulls small bundles of hair; in APMR, there is often very little hair to pull, supporting a diagnosis of alopecia rather than hair fragility. (General dermatology method, applied here with context.) Rare Diseases Information Center

8. Trichoscopy (handheld dermoscopy of scalp). A magnified look at follicles; helps rule out scarring alopecias and supports a syndromic alopecia diagnosis. (General clinical method aligned with alopecia evaluation.) Rare Diseases Information Center

9. Age-standardized developmental tools. Brief manual screening tools (e.g., Denver-style checklists) help quantify delay and guide referrals. (General pediatric practice for syndromic delay.) Rare Diseases Information Center

10. Bedside vision and cranial-nerve checks. Ensures no coexisting ocular motor issues; important for learning plans even if not a core feature of APMR. (General syndromic assessment.) Rare Diseases Information Center

C) Laboratory and pathological tests

11. Genetic testing panel for APMR/alopecia + neurodevelopment. Prioritized sequencing of LSS and AHSG, with reflex to broader neuro-dermal panels if negative. This is the key test that can confirm a molecular diagnosis. MalaCards+1

12. Exome or genome sequencing. If panels are negative, exome/genome can find rare or novel variants and explore APMR2/APMR3 regions or other candidate genes. PubMed

13. Chromosomal microarray/CNV analysis. Looks for small deletions/duplications that remove exons or change gene dosage in APMR genes/regions. NCBI

14. Targeted familial testing. When a variant is found in a child, testing parents and siblings confirms recessive inheritance and guides counseling. Orpha

15. Basic metabolic labs (screening role). While usually normal in APMR, routine labs help exclude other causes of hair loss or developmental delay (e.g., thyroid, iron, B12) during the initial work-up. (General diagnostic hygiene.) Rare Diseases Information Center

D) Electrodiagnostic tests

16. Electroencephalogram (EEG). Recommended if there are spells concerning for seizures; EEG abnormalities were reported in early case descriptions. PubMed

17. Auditory brainstem response (ABR) or formal audiology. Confirms the degree and type of hearing loss when screening is abnormal. Rare Diseases Information Center

18. Nerve-conduction/EMG (selected cases). Not routinely needed, but can be considered if tone changes suggest a peripheral component; most APMR issues are central. (General rationale.) Rare Diseases Information Center

E) Imaging tests

19. Brain MRI (when neurologic signs or seizures are present). Looks for structural brain changes sometimes seen in genetic neurodevelopmental disorders; results can be normal or nonspecific in APMR. (General approach, used in reports.) PubMed

20. High-resolution scalp photography (clinical documentation). Not a medical image in the radiology sense, but standardized photos help track hair status over time and support dermatology consultations. (Clinical practice point.) Rare Diseases Information Center

Non-pharmacological treatments (therapies & others)

(Each item includes a short description, purpose, and “how it helps”.)

1. Early developmental intervention
   Description: Start structured play-based learning and therapy soon after diagnosis.
   Purpose: Build language, thinking, self-care, and social skills.
   Mechanism: Repetition and guided practice strengthen brain pathways during the most plastic years.

2. Speech-language therapy
   Description: Regular sessions to improve understanding, expression, and swallowing if needed.
   Purpose: Boost communication and safe feeding.
   Mechanism: Targets articulation, vocabulary, and oromotor control through graded exercises.

3. Occupational therapy (OT)
   Description: Activities to improve hand use, sensory processing, and daily living (dressing, feeding).
   Purpose: Increase independence at home and school.
   Mechanism: Task-specific practice builds fine-motor circuits and adaptive strategies.

4. Physiotherapy (PT)
   Description: Stretching, strengthening, posture and gait training.
   Purpose: Reduce stiffness/hypertonia and improve mobility.
   Mechanism: Repeated movement retrains neuromuscular control and prevents contractures.

5. Hearing rehabilitation
   Description: Fitting of hearing aids; cochlear implant candidacy if severe loss.
   Purpose: Maximize sound access to support language and learning.
   Mechanism: Technology amplifies or bypasses damaged inner-ear hair cells to stimulate the auditory nerve. Rare Diseases Information Center

6. Educational supports & special education
   Description: Individualized education plans (IEPs), classroom accommodations.
   Purpose: Match teaching pace/materials to the child’s needs.
   Mechanism: Adapted curricula reduce cognitive load and allow mastery.

7. Behavioral therapy (e.g., ABA-informed strategies)
   Description: Positive reinforcement, visual schedules, and de-escalation tools.
   Purpose: Manage frustration, attention, and routines.
   Mechanism: Consistent cues and rewards shape behavior and reduce anxiety.

8. Communication aids (AAC)
   Description: Picture boards, tablets, or speech-generating devices.
   Purpose: Give a voice when speech is limited.
   Mechanism: Alternative channels lower the barrier to expressing needs and learning.

9. Family and caregiver training
   Description: Coaching on daily routines, therapy carryover, and seizure first-aid.
   Purpose: Make home a therapeutic environment; ensure safety.
   Mechanism: High-frequency practice at home multiplies gains from clinic therapy.

10. Sleep hygiene program
    Description: Fixed schedules, calming routines, light control, and consistent wake times.
    Purpose: Improve sleep quality, which helps learning and behavior.
    Mechanism: Regular circadian cues reset the sleep–wake clock.

11. Scalp and skin protection
    Description: Sunscreen on scalp, hats, gentle cleansers, emollients.
    Purpose: Prevent sunburn and irritation due to absent hair.
    Mechanism: UV shielding and barrier support protect exposed skin.

12. Psychological support & counseling
    Description: Child and family counseling, peer support groups.
    Purpose: Reduce stress, support coping, and improve adherence.
    Mechanism: Skills training and social connection buffer caregiver and child strain.

13. Nutritional counseling
    Description: Balanced protein, vitamins, and minerals; strategies for picky eating.
    Purpose: Support growth, immunity, and therapy stamina.
    Mechanism: Adequate nutrients aid brain and muscle function.

14. Vision assessment and correction
    Description: Regular eye exams; glasses if needed.
    Purpose: Optimize visual input to support learning.
    Mechanism: Clearer sensory input improves attention and development.

15. Safety planning for seizures
    Description: Water safety, helmet use when appropriate, supervision during high-risk activities.
    Purpose: Reduce injury risk.
    Mechanism: Environmental modifications minimize harm if a seizure occurs. Rare Diseases Information Center

16. Care coordination / case management
    Description: A lead clinician coordinates neurology, audiology, genetics, therapy, and school services.
    Purpose: Reduce missed needs and duplicated visits.
    Mechanism: Shared plans and communication across teams.

17. Genetic counseling
    Description: Explain inheritance, carrier testing for parents/siblings, and future pregnancy options.
    Purpose: Informed family planning and early detection.
    Mechanism: Identifies carriers and discusses prenatal or preimplantation options. Rare Diseases Information Center

18. Orthotics and adaptive equipment
    Description: Braces, seating supports, standing frames as needed.
    Purpose: Improve posture, prevent contractures, enable participation.
    Mechanism: Proper alignment reduces spastic stress and aids function.

19. Social services & benefits navigation
    Description: Support for transportation, therapy funding, inclusive schooling.
    Purpose: Lower practical barriers to care.
    Mechanism: Resource linkage keeps therapy consistent.

20. Community integration & recreation
    Description: Inclusive sports, art, or music therapy.
    Purpose: Build confidence and social skills.
    Mechanism: Enjoyable practice of motor and communication skills reinforces learning.

---

Drug treatments

Important: Doses below are typical starting ranges for context only; the treating clinician must individualize based on age, weight, comorbidities, drug interactions, and local guidelines.

Seizures (antiepileptics): Evidence for these medicines comes from standard epilepsy care; there are no APMR-specific drug trials, so clinicians follow general pediatric epilepsy guidance.

1. Levetiracetam – Class: SV2A modulator. Dose/time: ~10 mg/kg/day divided BID, titrate (max often 40–60 mg/kg/day). Purpose: Broad seizure control. Mechanism: Modulates synaptic vesicle protein to dampen hyperexcitable circuits. Side effects: Irritability, somnolence. (Use per epilepsy guidelines.)

2. Valproate – Class: Broad-spectrum AED. Dose/time: ~10–15 mg/kg/day BID–TID; adjust to levels. Purpose: Generalized or mixed seizures. Mechanism: ↑GABA; sodium channel effect. Side effects: Weight gain, liver toxicity, teratogenicity (avoid in pregnancy/teen girls unless no alternative).

3. Lamotrigine – Class: Sodium channel blocker. Dose/time: slow titration; ~0.3 mg/kg/day increasing q1–2 weeks; BID dosing. Purpose: Focal/primary generalized seizures, mood benefit. Mechanism: Stabilizes membranes. Side effects: Rash (rare SJS—slow titration critical).

4. Topiramate – Class: AMPA/kainate antagonist; carbonic anhydrase effects. Dose/time: ~1–3 mg/kg/day, divide BID; titrate. Purpose: Focal/generalized seizures. Side effects: Cognitive slowing, appetite loss, kidney stones.

5. Clobazam – Class: Benzodiazepine. Dose/time: ~0.25–0.5 mg/kg/day qHS–BID. Purpose: Adjunct for refractory seizures. Side effects: Sedation, tolerance.

6. Rescue benzodiazepine (e.g., buccal midazolam or rectal diazepam) – Purpose: Stop a prolonged seizure per emergency plan. Side effects: Drowsiness, respiratory depression if repeated.

Spasticity / hypertonia:

7. Baclofen – Class: GABAB_BB​ agonist. Dose/time: ~5 mg TID (children: ~0.3 mg/kg/day in divided doses), titrate. Purpose: Reduce tone, ease therapy. Side effects: Sedation, hypotonia.

8. Tizanidine – Class: α2-agonist. Dose/time: low bedtime dose; slow titration. Purpose: Tone reduction. Side effects: Sleepiness, low BP, liver enzyme changes.

9. Botulinum toxin A (injected) – Class: Neuromuscular blocker. Dose/time: weight/target-muscle based every 3–6 months. Purpose: Focal spasticity relief. Side effects: Local weakness, pain.

Sleep / behavior / attention (as clinically indicated):

10. Melatonin – Class: Chronobiotic. Dose/time: ~1–3 mg 30–60 min before bed (peds often 1–5 mg). Purpose: Sleep onset. Side effects: Morning grogginess (usually mild).

11. Risperidone – Class: Atypical antipsychotic. Dose/time: 0.25–0.5 mg/day, titrate. Purpose: Severe irritability/aggression that blocks learning. Side effects: Weight gain, metabolic effects, extrapyramidal symptoms.

12. Aripiprazole – Class: Partial D2 agonist. Dose/time: 1–2 mg/day, titrate. Purpose: Irritability. Side effects: Akathisia, GI upset.

13. Guanfacine (or clonidine) – Class: α2-agonist. Dose/time: Guanfacine ER 1 mg daily; titrate. Purpose: Hyperactivity/impulsivity, sleep. Side effects: Sedation, low BP.

14. SSRI (e.g., sertraline) – Class: Antidepressant. Dose/time: low dose; slow titration. Purpose: Anxiety that interferes with school/therapy. Side effects: GI upset, activation.

Hearing-related support (not curative drugs but sometimes used):

15. Otic antibiotics (only if infections occur) – Purpose: Treat otitis media promptly to protect hearing. Side effects: Vary by agent; avoid ototoxic drops if tympanic membrane not intact.

Other supportive needs (only when clearly indicated):

16. Vitamin D (if deficient) – Class: Supplement. Dose/time: per labs (commonly 600–1000 IU/day in children; higher for deficiency repletion under clinician). Purpose: Bone health, muscle function. Side effects: Hypercalcemia if overdosed.

17. Iron (if iron-deficiency) – Class: Supplement. Dose/time: ~3 mg/kg/day elemental iron divided. Purpose: Correct anemia that worsens fatigue or attention. Side effects: Constipation.

18. Omega-3 (fish oil) – Class: Nutraceutical. Dose/time: per age/weight (commonly 250–500 mg EPA+DHA/day in children, higher if advised). Purpose: General cardiometabolic/brain support; modest evidence for attention in some children. Side effects: Fishy aftertaste.

19. Polyethylene glycol (if constipation) – Class: Osmotic laxative. Dose/time: as needed, per pediatric dosing. Purpose: Prevent pain that disrupts sleep/therapy. Side effects: Bloating.

20. Acetaminophen/ibuprofen (as needed) – Class: Analgesics/antipyretics. Purpose: Manage pains that limit participation. Side effects: Dosing limits; avoid ibuprofen with certain conditions.

(General treatment approach follows standard pediatric neurology/audiology care; condition-level guidance emphasizes symptom management rather than disease-specific drugs.) Rare Diseases Information Center

---

Dietary “molecular” supplements

There is no supplement proven to cure APMR, but nutrition can support growth, therapy stamina, and general health. Always check for interactions with medicines and test for true deficiencies.

1. Vitamin D – Dose by lab results; supports bone and muscle function. Mechanism: Regulates calcium/phosphate metabolism.

2. Iron – Dose for deficiency; improves anemia-related fatigue. Mechanism: Restores hemoglobin and enzyme function.

3. Omega-3 (EPA/DHA) – General brain health; may aid attention in some children. Mechanism: Membrane fluidity and anti-inflammatory signaling.

4. Calcium – Only if dietary intake is low; pairs with vitamin D for bones.

5. Zinc – If deficient; supports growth and immunity.

6. Vitamin B12 – If low; supports nerve myelination and cognition.

7. Folate – If low; supports cell division and neural function.

8. Iodine – If low (rare with iodized salt); supports thyroid function and growth.

9. Protein-rich nutrition – Adequate high-quality protein for muscle and brain development.

10. Fiber (soluble/insoluble) – For bowel regularity and comfort, which improves sleep and learning.

---

Immunity boosters,” “regenerative,” or “stem-cell” drugs

Transparent guidance: There are no validated immune-booster, regenerative, or stem-cell drugs proven safe and effective for Perniola-Krajewska-Carnevale (APMR) syndrome. Using such products outside of a regulated clinical trial can be risky and expensive, with potential harm. Safer alternatives are routine vaccinations, balanced nutrition, good sleep, physical activity, and prompt treatment of intercurrent illnesses. If you are interested in research participation, ask a clinical geneticist about registered clinical trials and natural-history studies—but avoid unregulated clinics. (This position aligns with rare-disease best practice and the fact that APMR care is supportive.) Rare Diseases Information Center

---

Surgeries or procedures

1. Cochlear implantation (when severe sensorineural hearing loss is confirmed and hearing aids are insufficient)
   Why it’s done: Improve access to sound to support language and learning.
   Procedure: Place an electrode array in the cochlea and a receiver under the skin; works with an external processor. Rare Diseases Information Center

2. Botulinum toxin injections for focal spasticity
   Why: Relieve tight muscles that block therapy or hygiene.
   Procedure: Outpatient injections into target muscles, repeated every few months.

3. Orthopedic surgery for fixed contractures or hip issues (only if severe and after therapy/orthoses)
   Why: Improve comfortable positioning or mobility.
   Procedure: Tendon lengthening/osteotomies planned by pediatric orthopedics.

4. Gastrostomy tube (if severe feeding/swallowing issues cause poor growth)
   Why: Ensure safe, adequate nutrition and medication delivery.
   Procedure: Endoscopic or surgical tube placement into the stomach.

5. Dental procedures under anesthesia (for severe cooperation challenges)
   Why: Complete necessary dental care safely.
   Procedure: Comprehensive dental work during one planned session.

---

Prevention & wellness tips

1. Genetic counseling for parents and adult siblings; discuss carrier testing and future pregnancy options. Rare Diseases Information Center

2. Early hearing checks and prompt treatment of ear infections to protect hearing. Rare Diseases Information Center

3. Seizure safety plan at home and school; teach rescue-medication steps.

4. Routine vaccinations to reduce preventable illnesses that can worsen seizures or delay therapy.

5. Sun protection (scalp and eyebrows/eyelids) with hats and sunscreen due to absent hair.

6. Balanced diet and hydration to sustain therapy and prevent constipation.

7. Regular sleep schedule to improve behavior and learning.

8. Therapy consistency (OT/PT/SLT) even when progress is slow—small gains add up.

9. Vision and dental checkups because sensory and oral health affect learning and comfort.

10. Care coordination so specialists and school share one plan.

---

When to see a doctor

• Right away / emergency: New or prolonged seizures, breathing problems during a seizure, severe head injury, dehydration from feeding difficulties.

• Soon (days): Sudden hearing changes, regression in skills, severe sleep disruption, worsening stiffness that limits movement.

• Routine: Regular follow-up with pediatrics, neurology, audiology, therapy teams, dentistry, and genetics to adjust plans as your child grows.

---

What to eat & what to avoid (simple guidance)

What to eat:
• A balanced plate: protein (eggs, fish, beans, dairy or alternatives), whole grains, colorful vegetables, fruits, and healthy fats (fish, olive/rapeseed oils).
• Calcium and vitamin D sources daily (or supplements if labs show low).
• Fiber-rich foods (oats, lentils, vegetables) and fluids to prevent constipation.

What to avoid:
• Extreme “miracle” diets or expensive supplements promising hair regrowth or cognitive cures—no evidence for APMR.
• Excess sugar-sweetened drinks (worsen sleep and behavior).
• Any supplement that interacts with seizure medicines (always check with your clinician).

---

FAQs

1. Is Perniola-Krajewska-Carnevale syndrome the same as APMR?
   Yes. It’s a recognized synonym for Alopecia–Intellectual Disability syndrome. Orpha+1

2. How rare is it?
   Extremely rare—reported in fewer than ~20 families worldwide. Rare Diseases Information Center

3. How is it inherited?
   Usually autosomal recessive. Parents are unaffected carriers. Orpha

4. Which genes are involved?
   APMR1 involves AHSG; APMR4 involves LSS; other loci have been mapped for APMR2 and APMR3. NCBI

5. What are the main signs?
   Hair loss from infancy plus developmental/intellectual disability; sometimes seizures, hearing loss, hypertonia. Rare Diseases Information Center

6. Is there a cure?
   No cure yet; treatment is supportive and symptom-focused. Rare Diseases Information Center

7. Does hair grow back?
   In most reports hair loss is persistent; cosmetic options (hats, wigs) are common. Rare Diseases Information Center

8. Can hearing be helped?
   Yes—hearing aids or cochlear implants (when indicated) can improve sound access. Rare Diseases Information Center

9. What about seizures?
   Managed with standard anti-seizure medicines and a rescue plan, tailored by neurology. (No APMR-specific drug yet.) Rare Diseases Information Center

10. Will my child learn to communicate?
    Many children improve with speech therapy and AAC tools; progress varies.

11. Are stem-cell or “immune booster” treatments recommended?
    No—there’s no proven benefit for APMR; discuss any research trials only with your specialist team.

12. Can future pregnancies be tested?
    Yes—if the family’s pathogenic variants are identified, prenatal or preimplantation testing can be discussed. Orpha

13. What specialists are needed?
    Pediatrics, neurology, audiology/ENT, genetics, dermatology, therapy (PT/OT/SLT), dentistry, and education services.

14. How is the diagnosis confirmed?
    By clinical pattern plus genetic testing for APMR genes (e.g., AHSG, LSS) through accredited labs. Orpha

15. Where can I read more?
    Orphanet, NORD/GARD, Global Genes, Monarch Initiative, and the original report by Perniola and colleagues are good starting points. SpringerLink+4Orpha+4Rare Diseases Information Center+4

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 13, 2025.

PDF Documents For This Disease Condition References